CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022
Revenue:
Total revenue		$ 57,424,000	$ 51,346,000
Expenses:
Research and development	[1]	40,621,000	63,392,000
Selling, general and administrative	[1]	70,095,000	67,073,000
Restructuring and related expenses	[1]	2,743,000	12,838,000
Total expenses		113,459,000	143,303,000
Loss from operations		(56,035,000)	(91,957,000)
Interest expense	[2]	(2,350,000)	(6,369,000)
Loss on extinguishment of debt			(3,034,000)
Interest income and other income (expense), net		9,116,000	8,545,000
Loss from continuing operations before income taxes		(49,269,000)	(92,815,000)
Provision for income tax expense		(5,924,000)	(9,000)
Net loss from continuing operations		(55,193,000)	(92,824,000)
Income from discontinued operations before income taxes			1,143,930,000
Provision for income tax expense			(178,974,000)
Net income from discontinued operations			964,956,000
Net Income (Loss)		$ (55,193,000)	$ 872,132,000
Net income (loss) per share:
Continuing operations - basic (in dollars per share)		$ (1.00)	$ (1.26)
Continuing operations - diluted (in dollars per share)		(1.00)	(1.26)
Discontinued operations - basic (in dollars per share)			13.11
Discontinued operations - diluted (in dollars per share)			13.11
Net income (loss) - basic (in dollars per share)		(1.00)	11.85
Net income (loss) - diluted (in dollars per share)		$ (1.00)	$ 11.85
Shares used to compute net income (loss) per share - basic		55,303	73,591
Shares used to compute net income (loss) per share - diluted		55,303	73,591
Viatris collaboration agreement
Revenue:
Total revenue		$ 57,201,000	$ 48,624,000
Viatris royalties (Non-US)
Revenue:
Total revenue		7,000	30,000
Collaboration revenue
Revenue:
Total revenue		$ 216,000	192,000
Licensing revenue
Revenue:
Total revenue			$ 2,500,000

[1] Amounts include share-based compensation expense as follows:

[2] Interest expense for the year ended December 31, 2023 was comprised of non-cash interest expense only.